• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

    1/5/23 4:32:40 PM ET
    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REPH alert in real time by email
    SC 13G/A 1 sctl-sc13ga_123122.htm AMENDMENT TO FORM SC 13G
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 2)

    Societal CDMO, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    75629F109

    (CUSIP Number)

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)
       
    ☐ Rule 13d-1(c)
       
    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

       
     

     

    CUSIP No . 75629F109   Page 2 of 7

     

     

    1

    NAME OF REPORTING PERSONS
    First Light Asset Management, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

    46-3521994

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    0

     
    6

    SHARED VOTING POWER

    8,571,870

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    8,571,870

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,571,870

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.14%

     
    12

    TYPE OF REPORTING PERSON

    IA

     
             

     

       
     

     

    CUSIP No . 75629F109 Page 3 of 7 

     

     

    1

    NAME OF REPORTING PERSONS
    Mathew P. Arens

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United State of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    0

     
    6

    SHARED VOTING POWER

    8,571,870

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    8,571,870

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,571,870

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.14%

     
    12

    TYPE OF REPORTING PERSON

    IN

     
                             

      

       
     

     

     

    CUSIP No. 75629F109   Page 4 of 7

     

     

    Item 1(a).   Name of Issuer:
        Societal CDMO, Inc.
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:
        1 E. Uwchlan Ave., Suite 112 Exton, PA 19341
         
    Item 2(a).   Name of Person Filing:
       

    This Schedule 13G is being jointly filed by the following:

     

    First Light Asset Management, LLC (the “Manager”)

    Mathew P. Arens (“Mr. Arens”)

       

     

    The Manager may be deemed to be the beneficial owner of the Issuer’s shares of common stock (the “Shares”). The Manager acts as an investment adviser to certain persons holding separately managed accounts with the Manager, each of whom has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, those shares. The Manager may also be deemed to be the beneficial owner of these shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls the Manager in his position as managing member and majority owner of the Manager. The Manager and Mr. Arens are filing this Schedule 13G/A with respect to these Shares pursuant to Rule 13d-1(b) under the Act.

     

    The Manager and Mr. Arens may be deemed to be the beneficial owner of the total amount of Shares set forth across from its or his respective name in Item 4 below. The filing of this Schedule 13G shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
       

    Each of the reporting persons identified in Item 2(a) has its principal business office at:

     

    3300 Edinborough Way, Suite 201, Edina, MN 55435

         
    Item 2(c).   Citizenship:
       

    First Light Asset Management, LLC – Delaware limited liability company

    Mathew P. Arens – United States citizen

         
    Item 2(d).   Title of Class of Securities:
        Common Stock, $0.01 par value
         
    Item 2(e).   CUSIP Number:
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

       
     

     

     

    CUSIP No . 75629F109   Page 5 of 7

     

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☒ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:
       

    First Light Asset Management, LLC – 8,571,870

    Mathew P. Arens – 8,571,870

         
      (b) Percent of class:
       

    First Light Asset Management, LLC – 10.14%

    Mathew P. Arens – 10.14%

     
         
      (c) Number of shares as to which such person has:
         
        (i) Sole power to vote or to direct the vote
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 0

           
        (ii) Shared power to vote or to direct the vote
         

    First Light Asset Management, LLC – 8,571,870

    Mathew P. Arens – 8,571,870

           
        (iii) Sole power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 0

           
        (iv) Shared power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 8,571,870

    Mathew P. Arens – 8,571,870

                 

     

     

       
     

     

    CUSIP No .  75629F109   Page 6 of 7

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    FIRST LIGHT ASSET MANAGEMENT, LLC

     

    Date: January 4, 2023

     
       
      By: /s/ Kurt T. Peterson  
      Name: Kurt T. Peterson  
      Title: Chief Compliance Officer  
       
     

     

    Date: January 4, 2023

     
     
      Signature: /s/ Mathew P. Arens  
      Name: Mathew P. Arens  

     

     

       
     

     

    CUSIP No . 75629F109   Page 7 of 7

     

     

    Exhibit A

    JOINT FILING AGREEMENT

     

     

    The Undersigned agree that the statement on Schedule 13G with respect to the common stock of Societal CDMO, Inc. dated as of January 4, 2023, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

     

      FIRST LIGHT ASSET MANAGEMENT, LLC  
       
      By: /s/ Kurt T. Peterson  
      Name: Kurt T. Peterson  
      Title: Chief Compliance Officer  
       
         
     
      Signature: /s/ Mathew P. Arens  
      Name: Mathew P. Arens  

     

       
    Get the next $REPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REPH

    DatePrice TargetRatingAnalyst
    10/12/2021Outperform
    William Blair
    More analyst ratings

    $REPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

      With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ:SCTL) to Initiate Trading on March 22, 2022 SAN DIEGO and GAINESVILLE, Ga., March 21, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a r

      3/21/22 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Fourth Quarter and Year End 2021 Financial Results

      Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2021. "At this time last yea

      3/1/22 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

      SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings. All construction and equipment installation related to this service expansion has been completed at the company's San Diego facility and final validation and commissioning activities are underway. The company expects that its new automated fill/finish line and lyophilization

      2/23/22 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Recro Pharma

      William Blair initiated coverage of Recro Pharma with a rating of Outperform

      10/12/21 7:16:48 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

      SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)

      2/14/24 3:53:17 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

      SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)

      2/14/24 2:27:06 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Recro Pharma Inc.

      SC 13G - Societal CDMO, Inc. (0001588972) (Subject)

      8/31/23 11:59:02 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lake Ryan David covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 0.13% to 800,557 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      2/6/24 5:31:29 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enloe J David Jr was granted 196,474 shares, increasing direct ownership by 18% to 1,295,414 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      1/26/24 6:00:30 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Ryan David was granted 110,025 shares and covered exercise/tax liability with 37,453 shares, increasing direct ownership by 10% to 801,579 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      1/26/24 5:59:39 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Financials

    Live finance-specific insights

    See more
    • Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

      SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 fr

      2/22/22 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Third Quarter 2021 Financial Results

      Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Agreements Further Expanding Customer Base Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third q

      11/9/21 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021

      SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, November 9, 2021 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 fro

      11/2/21 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    SEC Filings

    See more
    • Recro Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Societal CDMO, Inc. (0001588972) (Filer)

      11/28/23 4:14:11 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Recro Pharma Inc.

      10-Q - Societal CDMO, Inc. (0001588972) (Filer)

      11/8/23 4:13:18 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Societal CDMO, Inc. (0001588972) (Filer)

      11/8/23 4:11:37 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Recro Announces Executive Changes

      MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today. Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDM

      12/16/20 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care